PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) today announced it has consented to a stay, on mutually acceptable terms, of its patent infringement lawsuit against Neuralstem, Inc., pending reexamination by the U.S. Patent and Trademark Office (PTO) of the four patents that are the subject of the litigation. In its lawsuit, StemCells alleges Neuralstem’s contemplated stem cell products and drug screening and discovery services infringe the four patents. StemCells stated that Neuralstem’s petition to the PTO to reexamine these patents was expected given the scope of the issued claims in these patents, which cover Neuralstem’s current business, including the human spinal stem cells it uses.
